Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ODD +14% (guidance)
Other news:
- ALXO +116.8% (reports interim Phase 2 ASPEN-06 clinical trial results of Evorpacept for the treatment of advanced HER2-Positive Gastric Cancer)
- PNT +84.6% (to be acquired by Eli Lilly (LLY) for $12.50 per share)
- RNLX +8.7% (announces that Medicare prices kidneyintelX.dkd at $950)
- ATAI +7.3% (completes Phase 1 study of VLS-01)
- PDSB +6.8% (announces interim 24-month survival rate of 74% in immune checkpoint inhibitor naïve head and neck cancer patients treated with PDS0101 in combination with KEYTRUDA)
- SCU +5.5% (Boaz Weinstein raises bid for the company according to Bloomberg)
- COMM +3.5% (divests Home Networks in exchange for a 25% stake in Vantiva SA)
- AOUT +3.2% (approves $10 mln for share repurchases)
- LFMD +3% (LifeMD and Particle Health demonstrate the potential of using comprehensive electronic health record data to triage patients for GLP-1 Weight Management Therapy)
- HPQ +2.4% (10% owner Warren Buffett sold another 5125638 shares worth more than $132 mln)
- SAFE +1.9% (credit ratings upgraded)
- SMLP +1.7% (provides operational update; announces review of strategic alternatives)
- ASTL +1.4% (extends contract with X)
- ADEA +1.3% (files lawsuit against Shaw; Samsung enters into long-term agreement)
- STN +1.2% (to launch 2024 Strategic Plan and host Investor Day on December 5 2023)
Analyst comments:
- WRBY +3.9% (upgraded to Outperform from In-line at Evercore ISI)
- FVRR +2.8% (upgraded to Buy from Neutral at ROTH MKM)
- REYN +1.6% (upgraded to Neutral from Sell at Goldman)
- AB +0.9% (upgraded to Buy from Neutral at Goldman)